<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="EN" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">ANTIMICROB AGENTS CHEMOTHER</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC90214</article-id><article-id pub-id-type="pmcid-ver">PMC90214.1</article-id><article-id pub-id-type="pmcaid">90214</article-id><article-id pub-id-type="pmcaiid">90214</article-id><article-id pub-id-type="pmid">11083649</article-id><article-id pub-id-type="doi">10.1128/aac.44.12.3414-3424.2000</article-id><article-id pub-id-type="publisher-id">0860</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject></subj-group></article-categories><title-group><article-title>Mefloquine Pharmacokinetic-Pharmacodynamic Models: Implications for Dosing and Resistance</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Simpson</surname><given-names initials="JA">Julie A.</given-names></name><xref ref-type="aff" rid="N0x95d20a8.0x9cc3478">1</xref><xref ref-type="aff" rid="N0x95d20a8.0x9cc3478">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Watkins</surname><given-names initials="ER">Emmeline R.</given-names></name><xref ref-type="aff" rid="N0x95d20a8.0x9cc3478">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Price</surname><given-names initials="RN">Ric N.</given-names></name><xref ref-type="aff" rid="N0x95d20a8.0x9cc3478">2</xref><xref ref-type="aff" rid="N0x95d20a8.0x9cc3478">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Aarons</surname><given-names initials="L">Leon</given-names></name><xref ref-type="aff" rid="N0x95d20a8.0x9cc3478">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kyle</surname><given-names initials="DE">Dennis E.</given-names></name><xref ref-type="aff" rid="N0x95d20a8.0x9cc3478">6</xref><xref ref-type="author-notes" rid="FN151">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>White</surname><given-names initials="NJ">Nicholas J.</given-names></name><xref ref-type="aff" rid="N0x95d20a8.0x9cc3478">1</xref><xref ref-type="aff" rid="N0x95d20a8.0x9cc3478">2</xref><xref ref-type="author-notes" rid="FN150">*</xref></contrib></contrib-group><aff id="N0x95d20a8.0x9cc3478"> Faculty of Tropical Medicine, Mahidol University,<sup>1</sup> and  Department of Immunology and Medicine, U.S. Armed Forces Research Institute of Medical Sciences,<sup>6</sup> Bangkok, and  Shoklo Malaria Research Unit, Mae Sod 63110, Tak Province,<sup>4</sup> Thailand, and  Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Headington,<sup>2</sup> and  Wellcome Trust Centre for the Epidemiology of Infectious Diseases, University of Oxford, Oxford,<sup>3</sup> and  School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester,<sup>5</sup> United Kingdom</aff><author-notes><fn id="FN150"><label>*</label><p>Corresponding author. Mailing address: Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Rd., Bangkok 10400, Thailand. Phone: (66 2) 246 0832. Fax: (66 2) 246 7795. E-mail: <email>fnnjw@diamond.mahidol.ac.th</email>.</p></fn><fn id="FN151"><label>&#8224;</label><p>Present address: Division of Experimental Therapeutics, Walter Reed Army Institute of Research Washington, DC 20307.</p></fn></author-notes><pub-date pub-type="ppub"><month>12</month><year>2000</year></pub-date><volume>44</volume><issue>12</issue><issue-id pub-id-type="pmc-issue-id">2491</issue-id><fpage>3414</fpage><lpage>3424</lpage><history><date date-type="received"><day>11</day><month>10</month><year>1999</year></date><date date-type="rev-request"><day>11</day><month>4</month><year>2000</year></date><date date-type="accepted"><day>11</day><month>9</month><year>2000</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>12</month><year>2000</year></date></event><event event-type="pmc-live"><date><day>12</day><month>09</month><year>2002</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2019-10-31 10:56:17.363"><day>31</day><month>10</month><year>2019</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2000, American Society for Microbiology</copyright-statement><copyright-year>2000</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ac003414.pdf"/><abstract><p>Antimalarial resistance develops and spreads when spontaneously occurring mutant malaria parasites are selected by concentrations of antimalarial drug which are sufficient to eradicate the more sensitive parasites but not those with the resistance mutation(s). Mefloquine, a slowly eliminated quinoline-methanol compound, is the most widely used drug for the treatment of multidrug-resistant falciparum malaria. It has been used at doses ranging between 15 and 25 mg of base/kg of body weight. Resistance to mefloquine has developed rapidly on the borders of Thailand, where the drug has been deployed since 1984. Mathematical modeling with population pharmacokinetic and in vivo and in vitro pharmacodynamic data from this region confirms that, early in the evolution of resistance, conventional assessments of the therapeutic response &#8804;28 days after treatment underestimate considerably the level of resistance. Longer follow-up is required. The model indicates that initial deployment of a lower (15-mg/kg) dose of mefloquine provides a greater opportunity for the selection of resistant mutants and would be expected to lead more rapidly to resistance than de novo use of the higher (25-mg/kg) dose.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>